Caribou Biosciences, Inc. (NASDAQ:CRBU – Get Free Report) has been assigned a consensus recommendation of “Buy” from the five analysts that are covering the firm, MarketBeat reports.

BRISBANE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform ...

Survey of Neurocrine Biosciences’ Crenessity suggests strong uptake across all patient segments. Sales could reach ~$1B in 2030. Feel unsure about the market’s next move? Copy trade alerts ...

SAN DIEGO, CA / ACCESS Newswire / April 15, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for ...

The company claiming it can restore lost species also wants to patent them. Colossal Biosciences not only wants to bring back the woolly mammoth—it wants to patent it, too. MIT Technology Review ...

16:42 EDT Ensysce Biosciences (ENSC) files to sell 980,000 shares of common stock for holders Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze ...

Colossal Biosciences isn’t exactly a household name. But you’ve probably at least heard of some of their goals and “achievements:” bringing back woolly mammoths and dodo birds, creating “woolly mice” ...

We are initiating coverage of Bright Minds Biosciences with a Buy rating, as we believe the stock is undervalued. We see a key catalyst in the Phase 2 data readout for BMB-101, which is expected ...

Neurocrine Biosciences, Inc. has shown significant growth since its 1996 IPO, with a current stock price around $100, reflecting an 850% increase. Ingrezza is the flagship, >$2bn p.a. selling product.

Colossal Biosciences, known for its ambitious “de-extinction” efforts, recently announced three snowy-white dire wolf pups named Romulus, Remus, and Khaleesi, marking the first time the ...

Pacira (PCRX) BioSciences announced its board of directors has authorized a share repurchase program of up to an aggregate of $300M of the company’s common stock. The program replaces the prior ...

Scientists outside the company, Colossal Biosciences, say the pups aren’t really the same dire wolves that roamed North America during the last Ice Age. But they do represent an impressive feat ...